Biotronik launches 'ultra-high energy' ICD to correct abnormal heart rhythms

Inventra HF-T ICD--Courtesy of Biotronik

More and more heart failure patients are needing a higher shock than the standard delivered by implantable cardioverter-defibrillators to correct their heart rhythm. This week, Biotronik launched the first ICD in the U.S. that meets this need.

Patients with tachycardia, or an abnormally fast heart rate, often require an ICD to convert dangerous arrhythmias to a normal heart rate. ICDs must deliver sufficiently powerful shocks to the heart as soon as possible, the company said in a statement. Varying heart anatomies may cause a patient to need a stronger shock than is standard.

The Inventra HF-T ICD delivers “ultra-high” energy, with 42 joules on the first shock as compared to the 36- or 37-joule shocks given by traditional ICDs.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"For an increasing number of patients--specifically those with larger cardiac anatomy and lower ejection fraction--a shock that is higher than the standard 36-37 J may be needed to convert irregular arrhythmia," said Dr. Mark Mascarenhas, an electrophysiologist at Jersey Shore University Medical Center in Neptune, NJ, in the statement. "The sooner an effective shock can be delivered, the likelihood of survival increases for these patients. For such patients, a CRT-D that delivers ultra-high energy on the first shock has a higher chance of converting the irregular arrhythmia. With the availability of Inventra HF-T, more heart failure patients will be able to receive 42 J energy delivered upon the first shock and, hence, receive life-saving therapy."

Berlin-based Biotronik specializes in cardiac rhythm management and vascular solutions. Its other offerings include pacemakers to correct bradycardia, or abnormally slow heart rhythms, cardiac resynchronization therapy pacemakers and defibrillators and peripheral stent systems and balloon catheters.

Suggested Articles

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.